Mylan just signed a huge deal with Abbott Labs -- was it a good or a bad move?
Abbott Labs (ABT -0.20%) and Mylan (MYL) gave investors reason to cheer today. Mylan bought up Abbott's established pharmaceuticals portfolio in non-emerging, ex-U.S. markets for $5.3 billion in an all-stock deal.
Was it a good idea for Mylan shareholders?
In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give their take.
David Williamson owns shares of Abbott Laboratories. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
